Search the Newsreel

Weekly Recap: Q3 RevPAR boost and $0.73 quarterly dividend declared

Marriott International (MAR) reported a Q3 RevPAR boost, partly due to the World Cup, but anticipates a slight dip in Q4 because of U.S. midterms and Middle East issues. The company also announced a record 629,000-room pipeline, added 17,900 net rooms, and declared a …

Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026

Lakefront Biotherapeutics NV announced its earnings results for the half year ended June 30, 2026. The company reported a significant decrease in revenue to EUR 18.6 million from EUR 140.3 million a year ago, but achieved a net income of EUR 16.6 million, a …

Riot Platforms Inc (RIOT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI Data ...

This article first appeared on GuruFocus. Total Revenue: $174 million, a 14% increase year-over-year. GAAP Net Loss: $237 million, or $0.68 per diluted share. Adjusted EBITDA Loss: $70 million. Data Center Segment Revenue: $23 million, including $4.9 million in operating lease revenue. Operating Lease …

Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln

Hong Kong Market Midday Commentary | All three major indices declined, with the Hang Seng Tech Index down 1.27%; tech and internet stocks fell, with Kuaishou and JD.com each dropping nearly 3%; biotech stocks rose, as GenScript Biotech surged over 8

Riot Platforms stock jumps 25% after-hours on $9.1 billion AI deal reportedly with Anthropic

Riot Platforms announced a 20-year, $9.1 billion data center lease agreement with an unnamed "leading frontier AI lab," which Bloomberg reported to be Anthropic. This deal, along with a prior agreement with AMD, brings Riot's long-term contracted revenue to $9.8 billion. Following the announcement, …

Sana Biotechnology | 10-Q: Quarterly report

This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.

Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for …

If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today

Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company …

Is Riot Platforms (RIOT) Undervalued As Q2 Earnings And Its AI Deal Reshape The Story?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Riot Platforms Q2 2026 earnings snapshot Riot Platforms (RIOT) reported second quarter 2026 results …

Lakefront Biotherapeutics H1 2026 Results: Net profit turns positive at €16.6 million

Lakefront Biotherapeutics reported a net profit of €16.6 million for H1 2026, a significant turnaround from a €259.1 million loss in H1 2025, primarily due to reduced R&D costs and positive fair value adjustments. The company completed the acquisition of Ouro Medicines, maintains a …

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Earnings Results, Beats Expectations By $1.01 EPS

Sana Biotechnology Q2 Results: Adj. EPS beats estimate

Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of …

Informe de resultados: Riot Platforms registra pérdidas en el segundo trimestre de 2026 mientras avanza en centros de datos

Sana Biotechnology falls 5% despite beating earnings estimates

Lakefront Biotherapeutics H1 FY26 net sales drop 87% to EUR 18.6 million; operating loss narrows 54% to EUR 107.2 million

Lakefront Biotherapeutics reported a significant drop in H1 FY26 net sales by 87% to €18.6 million, though it swung to a net profit of €16.6 million and narrowed its operating loss by 54% to €107.2 million. The company's R&D and SG&A expenses also decreased, …

Riot Platforms (RIOT) posts big H1 2026 loss while locking in $9.1B AI data lease

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target …

Sana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers

RA Capital Management, L.P. and affiliated entities have reported a 9.9% beneficial ownership in SAB Biotherapeutics (SABS), totaling 9,609,852 shares. This updated filing, Amendment No. 3 to Schedule 13D/A, clarifies that the change in ownership percentage is due to an increase in SAB's outstanding …

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics (NASDAQ: IOVA) recently reported strong Q2 earnings, with revenue increasing by 66% due to high demand for its cancer treatment, Amtagvi. The company also significantly reduced its net losses, leading to a surge in stock value and a new 52-week high. Despite …

Flash de resultados: Riot Platforms registra unos ingresos de 174,2 millones USD en el segundo trimestre, frente a los 154,3 millones USD previstos por FactSet

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Sana Biotechnology (SANA) warns on going concern amid $110.8M loss

Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12

Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, …

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The …

Riot Platforms and MARA Drop 6%, CleanSpark Sinks 5% as Strategy Sells Bitcoin, Shares

Quick Read RIOT and MARA each fell 6% after Strategy's 8-K revealed Saylor sold 1,690 Bitcoin below the firm's $75,385 average cost basis. Strategy (MSTR) sold Bitcoin at a realized loss, with the board authorizing up to $1.25 billion in total sales to build …

UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65

UBS has initiated coverage on First Tracks Biotherapeutics (TRAX.US) with a "Buy" rating. The investment bank also announced a target price of $65 for the company's stock. This initiation suggests a positive outlook from UBS on the future performance of First Tracks Biotherapeutics.

Riot jumps as Q2 revenue beats analyst expectations, landmark data center lease announced (RIOT:NASDAQ)

Riot Platforms (RIOT) saw its shares jump after announcing second-quarter revenue that surpassed analyst expectations and a new data center lease. The company reported a 14% year-over-year increase in total revenue, reaching $174.2 million. This positive financial news led to a 4.23% rise in …

Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS

Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts …

Samsara (IOT) Maintains 30% Growth as Margins Improve and AI Risks Stay Low

Sands Capital, an investment management company, released its "Sands Capital Technology Innovators Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, global equities rebounded sharply, with the MSCI ACWI posting its strongest quarterly gain since 2020, …

Piper Sandler downgrades Samsara to neutral on weakening app downloads

Investing.com -- Piper Sandler downgraded Samsara to Neutral from Overweight and reiterated a $40 price target, citing deteriorating app-download trends, tougher second-half comparisons and a shift toward cross-selling as a larger driver of growth. The firm said the setup remains de-risked, particularly for free …

Legend Biotech in spotlight: Earnings test Carvykti momentum

Legend Biotech is set to report its second-quarter earnings, with investors focused on the sustained growth of its CAR-T therapy, Carvykti, amidst increasing competition and a recent CEO departure. Analysts anticipate improved earnings and revenue for the quarter, but concerns linger regarding competitive threats …